IT

ITM Isotope Technologies Munich is a leading radiopharmaceutical company dedicated to developing, producing, and globally distributing high-quality diagnostic and therapeutic radiopharmaceuticals and radioisotopes for cancer treatment. The company's core focus is on Targeted Radionuclide Therapy, which utilizes precise targeting molecules like peptides or antibodies coupled with medical radioisotopes to deliver radiation directly to tumor cells. ITM's lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide), is currently in Phase 3 clinical trials for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Beyond its internal pipeline, ITM is a major global supplier of medical radioisotopes, including no-carrier-added Lutetium-177 and Actinium-225, supporting the broader radiopharmaceutical industry.